At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RVMD Revolution Medicines, Inc.
Closed 04-14 16:00:00 EDT
147.01
+10.71
+7.86%
盘后146.95
-0.06-0.04%
19:57 EDT
High148.00Low134.66Vol8.20M
Open136.50D1 Closing136.30Amplitude9.79%
Mkt Cap29.13BTradable Cap26.31BTotal Shares198.17M
T/O1.17BT/O Rate4.58%Tradable Shares179.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Revolution Medicines Facing Further Upside After Daraxonrasib's Results, RBC Says
MT Newswires Live  ·  04-14 23:42
Revolution Medicines Facing Further Upside After Daraxonrasib's Results, RBC Says
BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug
Reuters  ·  04-14 21:38
BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug
Revolution Medicines Reports Positive Phase 3 Trial Results for Pancreatic Cancer Drug
Deep News  ·  04-14 21:13
Revolution Medicines Reports Positive Phase 3 Trial Results for Pancreatic Cancer Drug
Revolution Medicines price target raised to $200 from $140 at Evercore ISI
TIPRANKS  ·  04-14 19:56
Revolution Medicines price target raised to $200 from $140 at Evercore ISI
RBC Raises Price Target on Revolution Medicines to $162 From $140, Keeps Outperform, Speculative Risk
MT Newswires Live  ·  04-14 19:47
RBC Raises Price Target on Revolution Medicines to $162 From $140, Keeps Outperform, Speculative Risk
Revolution Medicines Inc : H.c. Wainwright Raises Target Price to $169 From $73
THOMSON REUTERS  ·  04-14 18:11
Revolution Medicines Inc : H.c. Wainwright Raises Target Price to $169 From $73
Revolution Medicines Inc : RBC Raises Target Price to $162 From $140
THOMSON REUTERS  ·  04-14 12:11
Revolution Medicines Inc : RBC Raises Target Price to $162 From $140
Revolution Medicines files to sell $750M of common stock
TIPRANKS  ·  04-14 05:10
Revolution Medicines files to sell $750M of common stock
BRIEF-Revolution Medicines, Inc. Announces Proposed Offerings Of Common Stock And Convertible Senior Notes
Reuters  ·  04-14 04:54
BRIEF-Revolution Medicines, Inc. Announces Proposed Offerings Of Common Stock And Convertible Senior Notes
Revolution Medicines Shares Down 1.6% After the Bell; Announces Proposed Offerings of Common Stock and Convertible Senior Notes
THOMSON REUTERS  ·  04-14 04:20
Revolution Medicines Shares Down 1.6% After the Bell; Announces Proposed Offerings of Common Stock and Convertible Senior Notes
Revolution Medicines plans USD 750 million follow-on common stock offering
Reuters  ·  04-14 04:03
Revolution Medicines plans USD 750 million follow-on common stock offering
Revolution Medicines Inc - to Offer $750 Mln Common Stock and $250 Mln Convertible Senior Notes Due 2033
THOMSON REUTERS  ·  04-14 04:01
Revolution Medicines Inc - to Offer $750 Mln Common Stock and $250 Mln Convertible Senior Notes Due 2033
BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
Reuters  ·  04-14 01:50
BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
Revolution Medicines Is Maintained at Outperform by Oppenheimer
Dow Jones  ·  04-14 00:56
Revolution Medicines Is Maintained at Outperform by Oppenheimer
Bar remains unchanged for Erasca after Revolution’s ‘clear win,’ says Jefferies
TIPRANKS  ·  04-14 00:11
Bar remains unchanged for Erasca after Revolution’s ‘clear win,’ says Jefferies
Revolution Medicines rises 37.9%
TIPRANKS  ·  04-14 00:00
Revolution Medicines rises 37.9%
BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma
Reuters  ·  04-13 23:43
BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma
Top Midday Stories: Goldman Shares Fall Despite Q1 Earnings Topping Estimates; Revolution's Pancreatic Cancer Drug Met Key Study Goals
MT Newswires Live  ·  04-13 23:40
Top Midday Stories: Goldman Shares Fall Despite Q1 Earnings Topping Estimates; Revolution's Pancreatic Cancer Drug Met Key Study Goals
Revolution Medicines Inc : Oppenheimer Raises Target Price to $165 From $150
THOMSON REUTERS  ·  04-13 23:06
Revolution Medicines Inc : Oppenheimer Raises Target Price to $165 From $150
Revolution Medicines Up Over 35%, on Track for Record High Close -- Data Talk
Dow Jones  ·  04-13 22:53
Revolution Medicines Up Over 35%, on Track for Record High Close -- Data Talk

Introduction

Company Name.
Revolution Medicines, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Issue price:
--